IGT Biologika’s COVID-19 vaccine becomes third in Germany to be approved for human trials

pharmafile | October 2, 2020 | News story | Medical Communications, Research and Development COVID-19, IDT Biologika, Vaccine 

German biotech IDT Biologika has become the third company in the country to secure approval from the nation’s vaccine regulator to progress into human trials of its prophylactic therapy for the prevention of COVID-19 infection, it has emerged.

IDT Biologika’s candidate is currently being developed in partnership with the German Centre for Infection Research (DZIF), and follows in the steps of vaccine therapies from other German firms BioNTech and CureVac, which both secured approval for human testing earlier this year.

In the first planned study, the vaccine will be tested in 30 participants between the ages of 18 and 55, administered in two doses every four weeks.

Should the first study prove successful, the company plans to push the therapy into Phase 2 trials in older patients before the end of the year.

Klaus Cichutek, Head of the Paul Ehrlich Institut, the Federal Institute for Vaccines and Biomedicines and part of the German Federal Ministry of Health explained: “If data from Phase 3 trials shows the vaccines are effective and safe, the first vaccines could be approved at the beginning of the year, possibly with conditions attached…Based on assurances from manufacturers, the first doses for people in Germany will be available at that time, in accordance with the priorities set by the Standing Committee on Vaccination.”

IDT Biologika is currently involved in the development of six different COVID-19 vaccine projects.

Matt Fellows

Related Content

FDA approves Pfizer’s RSV vaccine for older adults

Global pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has …

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …


FDA committee votes in favour of Pfizer’s RSV vaccine for maternal immunisation

Pfizer has announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) from the …

Latest content